Hitchhiking drug targets Hard-to-Treat cancers in early trial

NCT ID NCT05352750

Ongoing Disease control Sponsor: Sonnet BioTherapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. The main goals are to check safety, find the best dose, and see how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SON-1010 (IL12-FHAB), a biologic drug that carries interleukin-12 to tumors by binding to albumin in the blood
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that are hard to treat.
What could go wrong: This is a very early Phase 1 trial with only 42 people, so it is mainly checking safety and dosing. The drug may not shrink tumors or could cause side effects like immune overactivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR SOFT TISSUE SARCOMA ADULT

Contacts and locations

Locations

Sarcoma Oncology Center

Santa Monica, California, 90403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.